Guardant Health Inc. (GH)
Market Closed
17 Jul, 20:00
$
155. 87
+0.87
+0.5613%
$
21.22B Market Cap
- P/E Ratio
- Div Yield
1.98M Volume
-3.59 Eps
$ 155
Previous Close Want to track GH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
GH closed today higher at $155.87, an increase of 0.5613% from yesterday's close, completing a monthly increase of 22.7323% or $28.87. Over the past 12 months, GH stock gained 52.3656%.
GH is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0.809%. On average, the company has surpassed earnings expectations by 0.4947%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seekingalpha | 2 months ago
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Seekingalpha | 2 months ago
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks | 2 months ago
Guardant Health Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 191 | $7,721.02 | $31,171.22 | $23,450.2 | 303.72% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $10,214 | $16,320.01 | $6,106.01 | 59.78% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 72 | $6,829.5 | $11,748.96 | $4,919.46 | 72.03% |
 Farallon Capital Farallon Capital Management LLC | 8,000 | $817,120 | $1.31M | $492,240 | 60.24% |
| BG Bart Gancher Intech Investment Management LLC | 31,499 | $1.19M | $5.14M | $3.95M | 330.94% |
Guardant Health Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Patrick Donnelly Citigroup | 358.47 | $55,982.94 | $58,416.98 | $2,434.04 | 4.35% |
 Mark Massaro BTIG | 35.55 | $3,187.19 | $5,793.9 | $2,606.71 | 81.79% |
| EK Evie Koslosky Goldman Sachs | 394.72 | $49,581.13 | $61,620.17 | $12,039.04 | 24.28% |
Guardant Health Inc. (GH) FAQ
What is the stock price today?
The current price is $155.87.
On which exchange is it traded?
Guardant Health Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is GH.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 21.22B.
Has Guardant Health Inc. ever had a stock split?
No, there has never been a stock split.
Guardant Health Inc. Profile
| Professional Services Industry | Industrials Sector | Helmy Eltoukhy CEO | NASDAQ (NGS) Exchange | 40131M109 CUSIP |
| US Country | 2,506 Employees | - Last Dividend | - Last Split | 4 Oct 2018 IPO Date |
Overview
Guardant Health, Inc. is a pioneer in the precision oncology field, dedicated to enhancing cancer management through a comprehensive portfolio of blood and tissue tests, expansive data sets, and sophisticated analytics. Operating both within the United States and internationally, this company leverages cutting-edge technology to transform cancer care, making it more personalized and effective. Since its establishment in 2011, Guardant Health has been at the forefront of innovation in oncology, partnering with key industry players like Illumina, Inc., to push the boundaries of cancer research and treatment further.
Products and Services
- Guardant360: A liquid biopsy test that offers comprehensive genomic profiling of cancer from a simple blood draw, enabling non-invasive tumor genetic analysis.
- Guardant360 LDT: An extension of the Guardant360 service, tailored for more specific diagnostic needs through a laboratory-developed test approach.
- Guardant360 CDx Test: Designed as a companion diagnostic tool, this test helps in identifying patients who could benefit from specific cancer therapies based on their genetic markers.
- Guardant360 Response Test: This test monitors treatment response and disease progression, aiding in the timely adjustment of therapeutic strategies.
- Guardant360 TissueNext Test: Offers a more comprehensive genetic profile by combining blood-based and tissue-based genomic testing, ensuring no valuable data is missed.
- GuardantINFINITY Test: Aimed at providing a deeper understanding of tumor genetics over time, this test is crucial for uncovering resistance mechanisms and guiding long-term treatment plans.
- GuardantConnect: An integrated software solution that connects patients with actionable genetic alterations to clinical studies, improving accessibility to innovative treatments.
- GuardantOMNI Test: Focused on patients with advanced-stage cancer, this test screens for a broad array of genetic markers to inform treatment decisions.
- GuardantINFORM: A research platform that utilizes in-silico modeling to explore tumor evolution and resistance mechanisms across various cancers, aiding in the development of next-generation therapies.
- Shield Test: A novel approach for early cancer detection through the analysis of blood samples, aiming to improve survival rates through early intervention.
- Guardant Reveal Test: Specifically designed for early-stage cancer patients, this test guides adjuvant treatment selection to minimize recurrence risk.
- Smart Liquid Biopsy Platform: This innovative platform supports the development of precision oncology by offering flexible, scalable, and accurate liquid biopsy testing.
- Guardant Galaxy: An AI-backed digital pathology platform that enhances the detection of cancer biomarkers, leveraging artificial intelligence to improve diagnostic accuracy.
Contact Information
Address: 505 Penobscot Drive
Phone: 855 698 8887
Website: https://guardanthealth.com
